Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

February 21, 2023

Study Completion Date

February 21, 2023

Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
DRUG

AMG 427

AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.

Trial Locations (16)

3004

The Alfred Hospital, Melbourne

3050

The Royal Melbourne Hospital, Parkville

10065

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

21287

Johns Hopkins, Baltimore

27710

Duke University Medical Center, Durham

60208

Northwestern University, Evanston

77030

University of Texas MD Anderson Cancer Center, Houston

81377

Klinikum der Universitaet Muenchen Campus Grosshadern, München

91010

City of Hope National Medical Center, Duarte

M5G 2M9

University Health Network-Princess Margaret Cancer Centre, Toronto

01307

Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden

277-8577

National Cancer Center Hospital East, Kashiwa-shi

910-1193

University of Fukui Hospital, Yoshida-gun

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital Yonsei University Health System, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY